Epidemiological evidence increasingly supports apo B as a superior predictor of CVD risks compared with traditional markers of dyslipidaemia—such as total cholesterol or LDL cholesterol [41,42]. The gene discussed is APOB; the disease is inherited lipid metabolism disorder.